Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 917 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact917 DOIs

DOIs for this ISSN

Showing the top 5 of 9999 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Confidence and Receptivity for COVID-19 Vaccines: A Rapid Sy… (10.3390/vaccines9010016)	ORCID	69.84	621
2	Vaccine Adjuvants: from 1920 to 2015 and Beyond (10.3390/vaccines3020320)	ORCID	68.65	556
3	Developments in Viral Vector-Based Vaccines (10.3390/vaccines2030624)	ORCID	64.21	369
4	A Comparison of Plasmid DNA and mRNA as Vaccine Technologies (10.3390/vaccines7020037)	ORCID	64.18	368
5	Challenges of Storage and Stability of mRNA-Based COVID-19 V… (10.3390/vaccines9091033)	ORCID	63.25	338
6	The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppressi… (10.3390/vaccines3030703)	ORCID	62.73	322
7	The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistan… (10.3390/vaccines4030022)	ORCID	62.35	311
8	Recent Advances in Subunit Vaccine Carriers (10.3390/vaccines4020012)	ORCID	61.02	275
9	Human Papillomavirus Vaccines: An Updated Review (10.3390/vaccines8030391)	ORCID	60.86	271
10	Nanoparticle Drug Delivery Systems Designed to Improve Cance… (10.3390/vaccines3030662)	ORCID	59.73	244
11	Whole Tumor Antigen Vaccines: Where Are We? (10.3390/vaccines3020344)	ORCID	59.60	241
12	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond (10.3390/vaccines9020147)	ORCID	59.60	241
13	Progress and Prospects on Vaccine Development against SARS-C… (10.3390/vaccines8020153)	ORCID	58.16	211
14	Cholera Toxin Subunit B as Adjuvant––An Accelerator in Prote… (10.3390/vaccines3030579)	ORCID	57.08	191
15	Approaches and Perspectives for Development of African Swine… (10.3390/vaccines5040035)	ORCID	55.44	164
16	Better Adjuvants for Better Vaccines: Progress in Adjuvant D… (10.3390/vaccines8010128)	ORCID	54.47	150
17	Vector Design for Improved DNA Vaccine Efficacy, Safety and… (10.3390/vaccines1030225)	ORCID	53.81	141
18	Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics… (10.3390/vaccines9070767)	ORCID	53.73	140
19	Immune Adjuvant Effect of Molecularly-defined Toll-Like Rece… (10.3390/vaccines2020323)	ORCID	53.58	138
20	CpG Oligonucleotides as Cancer Vaccine Adjuvants (10.3390/vaccines3020390)	ORCID	52.51	125
21	Current State of Global African Swine Fever Vaccine Developm… (10.3390/vaccines8030531)	ORCID	52.16	121
22	Selecting Target Antigens for Cancer Vaccine Development (10.3390/vaccines8040615)	ORCID	52.07	120
23	Immunosenescence: Aging and Immune System Decline (10.3390/vaccines12121314)	ORCID	51.80	117
24	Leptin-Induced JAK/STAT Signaling and Cancer Growth (10.3390/vaccines4030026)	ORCID	51.70	116
25	Overwhelming Evidence for a Major Role for Herpes Simplex Vi… (10.3390/vaccines9060679)	ORCID	51.33	112
26	Natural and Synthetic Saponins as Vaccine Adjuvants (10.3390/vaccines9030222)	ORCID	51.23	111
27	Live-Attenuated Bacterial Vectors: Tools for Vaccine and The… (10.3390/vaccines3040940)	ORCID	50.94	108
28	Optimal Use of Vaccines for Control of Influenza A Virus in… (10.3390/vaccines3010022)	ORCID	50.73	106
29	Harnessing the Power of T Cells: The Promising Hope for a Un… (10.3390/vaccines6020018)	ORCID	50.63	105
30	Efforts at COVID-19 Vaccine Development: Challenges and Succ… (10.3390/vaccines8040739)	ORCID	50.53	104
31	Viral Inhibition of the IFN-Induced JAK/STAT Signalling Path… (10.3390/vaccines4030023)	ORCID	50.22	101
32	Targeting Innate Immunity in Cancer Therapy (10.3390/vaccines9020138)	ORCID	50.11	100
33	Vaccinations and Autoimmune Diseases (10.3390/vaccines9080815)	ORCID	50.11	100
34	Yellow Fever: Origin, Epidemiology, Preventive Strategies an… (10.3390/vaccines10030372)	ORCID	49.89	98
35	Commercial PRRS Modified-Live Virus Vaccines (10.3390/vaccines9020185)	ORCID	49.78	97
36	Targeting COVID-19 Vaccine Hesitancy in Minority Populations… (10.3390/vaccines9050489)	ORCID	49.67	96
37	Development of mRNA Vaccines: Scientific and Regulatory Issu… (10.3390/vaccines9020081)	ORCID	48.98	90
38	Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine S… (10.3390/vaccines2020252)	ORCID	48.36	85
39	Advances in RNA Vaccines for Preventive Indications: A Case… (10.3390/vaccines7040132)	ORCID	47.98	82
40	Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuv… (10.3390/vaccines12060619)	References ORCID	47.71	8
41	Pseudomonas aeruginosa: Recent Advances in Vaccine Developme… (10.3390/vaccines10071100)	ORCID	47.58	79
42	Replicon RNA Viral Vectors as Vaccines (10.3390/vaccines4040039)	ORCID	47.58	79
43	Enlisting the mRNA Vaccine Platform to Combat Parasitic Infe… (10.3390/vaccines7040122)	ORCID	47.44	78
44	Advancements in mRNA Encoded Antibodies for Passive Immunoth… (10.3390/vaccines9020108)	ORCID	47.44	78
45	Efficacy and Safety of COVID-19 Vaccines in Phase III Trials… (10.3390/vaccines9060582)	ORCID	47.30	77
46	Why Reaching Zero-Dose Children Holds the Key to Achieving t… (10.3390/vaccines11040781)	ORCID	46.88	74
47	Integrating Immunologic Signaling Networks: The JAK/STAT Pat… (10.3390/vaccines4010005)	ORCID	46.88	74
48	A Systematic Review of Recent Advances in Equine Influenza… (10.3390/vaccines2040797)	ORCID	46.28	70
49	Mechanisms of Entry and Endosomal Pathway of African Swine F… (10.3390/vaccines5040042)	ORCID	46.28	70
50	Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants (10.3390/vaccines3030620)	ORCID	45.97	68